Photo from wikipedia
Patients with end‐stage kidney disease (ESKD) exhibit an elevated cardiovascular risk. Chronic inflammation is one of the main mechanisms of cardiovascular disease (CVD). Lipopolysaccharide has been proposed as a link… Click to show full abstract
Patients with end‐stage kidney disease (ESKD) exhibit an elevated cardiovascular risk. Chronic inflammation is one of the main mechanisms of cardiovascular disease (CVD). Lipopolysaccharide has been proposed as a link between systemic inflammation and CVD. Herein, we evaluated whether lipopolysaccharide‐binding protein (LBP), a surrogate marker of lipopolysaccharide and consequent inflammation, is associated with cardiovascular events in ESKD.
Keywords:
binding protein;
serum lipopolysaccharide;
lipopolysaccharide binding;
protein levels;
cardiovascular events
Journal Title: Nephrology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nephrology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!